Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013;65 Suppl 1(0 1):3-11.
doi: 10.1080/01635581.2013.785004.

Chemopreventive and anti-cancer efficacy of silibinin against growth and progression of lung cancer

Affiliations
Review

Chemopreventive and anti-cancer efficacy of silibinin against growth and progression of lung cancer

Samiha Mateen et al. Nutr Cancer. 2013.

Abstract

The use of systemic chemotherapeutic drugs and molecular-targeted therapies in the treatment of patients with locally advanced or metastatic lung cancer has its limitations due to the associated acute and cumulative dose limiting toxicities and acquisition of drug resistance. Prevention and therapeutic intervention by dietary agents including nutraceuticals which are non-toxic, cost-effective, and physiologically bioavailable, are emerging approaches in lung cancer management. In this regard, silibinin, a natural flavonolignan, has been rigorously evaluated for the prevention and growth control of lung cancer through extensive in vitro and in vivo studies. Successful studies conducted so far, have established that silibinin is effective both alone and in combination with other agents (e.g., chemotherapeutic and epigenetic agents) in significantly inhibiting the growth of lung cancer cells. In vivo, its effects have been shown to be mediated through inhibition of proliferation, angiogenesis and epigenetic-related events. Therefore, the present review focuses on encompassing the efficacy and mechanisms of silibinin against lung cancer.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: The authors declare that there are no conflicts to disclose.

Figures

Fig. 1
Fig. 1
Milk Thistle. (A) Silybum marianum (Milk Thistle) plant, Family: Asteraceae. (B) Seeds of Milk thistle plant. (C) Chemical structure of silibinin - the principle bioactive constituent of silymarin (milk thistle extract) isolated from the dried fruits and seeds of milk thistle.
Fig. 2
Fig. 2
Major molecular targets of silibinin involved in its efficacy against epithelial cancers. *, Key molecules that are targeted by silibinin in its chemopreventive and anti-cancer efficacy against lung cancer.

Similar articles

Cited by

References

    1. Amercian Cancer Society. Cancer Facts and Figures. 2012
    1. Denlinger CE, Ikonomidis JS, Reed CE, Spinale FG. Epithelial to mesenchymal transition: the doorway to metastasis in human lung cancers. J Thorac Cardiovasc Surg. 2010;140:505–513. - PubMed
    1. Travis WD. Classification of lung cancer. Semin Roentgenol. 2011;46:178–186. - PubMed
    1. Schiller JH. Current standards of care in small-cell and non-small-cell lung cancer. Oncology. 2001;61 (Suppl 1):3–13. - PubMed
    1. Collins LG, Haines C, Perkel R, Enck RE. Lung cancer: diagnosis and management. Am Fam Physician. 2007;75:56–63. - PubMed

Publication types